What is HC Wainwright’s Estimate for LXRX Q1 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – HC Wainwright issued their Q1 2025 EPS estimates for Lexicon Pharmaceuticals in a note issued to investors on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($0.09) for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q2 2025 earnings at ($0.09) EPS and Q3 2025 earnings at ($0.10) EPS.

A number of other analysts also recently weighed in on the stock. Leerink Partners reissued a “market perform” rating and set a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Piper Sandler decreased their price target on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Leerink Partnrs downgraded shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Trading Down 9.5 %

LXRX opened at $0.35 on Monday. The firm has a market capitalization of $87.34 million, a P/E ratio of -0.47 and a beta of 1.04. The firm’s 50 day moving average is $0.72 and its 200-day moving average is $1.12. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.83. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. The company had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. FMR LLC grew its position in shares of Lexicon Pharmaceuticals by 28.9% during the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock valued at $78,291,000 after buying an additional 11,179,919 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Lexicon Pharmaceuticals by 630.7% in the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock worth $6,638,000 after acquiring an additional 7,758,371 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in Lexicon Pharmaceuticals by 301.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company’s stock valued at $5,582,000 after acquiring an additional 5,676,021 shares during the period. Nantahala Capital Management LLC boosted its stake in Lexicon Pharmaceuticals by 186.6% in the fourth quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company’s stock valued at $4,877,000 after acquiring an additional 4,300,000 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Lexicon Pharmaceuticals by 8.4% in the third quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock valued at $5,534,000 after acquiring an additional 273,436 shares during the period. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.